title: Therapeutic advances in cutaneous T-cell lymphoma.
abstract: A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). In particular, with recent FDA approvals of the three new agents vorinostat (Zolinza), romidepsin (Istodax), and pralatrexate (Folotyn) CTCL treatment has been transformed. Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.
authors: Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
authors: Oleg E
authors: OE
authors: Akilov
authors: Larisa
authors: L
authors: Geskin
references: Clin Cancer Res. 2000 Sep;6(9):3493-8
references: 10999734
references: Skinmed. 2003 Sep-Oct;2(5):316-8
references: 14673267
references: J Clin Oncol. 2009 Sep 10;27(26):4357-64
references: 19652067
references: Photochem Photobiol. 1995 May;61(5):523-8
references: 7770514
references: J Clin Oncol. 2007 Jul 20;25(21):3109-15
references: 17577020
references: J Clin Oncol. 2009 Nov 10;27(32):5410-7
references: 19826128
references: J Clin Oncol. 2007 Sep 20;25(27):4293-7
references: 17709797
references: Clin Cancer Res. 2007 Apr 15;13(8):2318-22
references: 17438089
references: Dermatol Surg. 2000 Aug;26(8):765-9; discussion 769-70
references: 10940064
references: Br J Dermatol. 2010 Oct;163(4):884-5
references: 20854405
references: Br J Dermatol. 2009 Jul;161(1):167-9
references: 19298276
references: Recent Results Cancer Res. 2002;160:309-20
references: 12079229
references: Semin Oncol. 1999 Jun;26(3):276-89
references: 10375085
references: J Clin Oncol. 2010 May 10;28(14):2365-72
references: 20351328
references: Blood. 2003 Jun 1;101(11):4267-72
references: 12543862
references: Acta Derm Venereol. 2008;88(3):288-90
references: 18480938
references: N Engl J Med. 1989 Dec 28;321(26):1784-90
references: 2594037
references: J Clin Oncol. 2000 Jul;18(13):2603-6
references: 10893292
references: Bone Marrow Transplant. 2004 Mar;33(6):629-34
references: 14755323
references: Bone Marrow Transplant. 1991 Feb;7(2):133-7
references: 2049557
references: J Invest Dermatol. 1998 Sep;111(3):396-8
references: 9740230
references: Haematologica. 2007 Jun;92(6):784-94
references: 17550851
references: Curr Opin Oncol. 2006 Nov;18(6):591-7
references: 16988580
references: Cancer. 2003 Sep 1;98(5):993-1001
references: 12942567
references: Dermatology. 2003;207(1):116-8
references: 12835571
references: Leuk Res. 2008 Aug;32(8):1299-303
references: 18096224
references: Clin Cancer Res. 2002 Mar;8(3):718-28
references: 11895901
references: Eur J Haematol. 2003 Oct;71(4):250-6
references: 12950233
references: Bone Marrow Transplant. 2008 Apr;41(7):597-604
references: 18176611
references: Biosci Biotechnol Biochem. 1994 Sep;58(9):1579-83
references: 7765477
references: Blood. 2005 May 15;105(10):3768-85
references: 15692063
references: Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6
references: 19951879